home

Home> Latest Approval > Combination

Industry News
Latest Approval

U.S.FDA approved Orkambi (lumacaftor/ivacaftor) for cystic fibrosis

U.S.FDA approved Orkambi (lumacaftor/ivacaftor) for cystic fibrosis

CombinationPharmacodia.com2015-07-02 00:00 Read 337

On July 2, 2015, FDA approved Orkambi (lumacaftor/ivacaftor) to treat cystic fibrosis (CF) in patients 12 years and older, who have the F508del mutation, which causes the production of an abnormal protein that disrupts how water and chloride are transported in the body. Orkambi becomes the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation.

First Prev 1 2 Next Last Total 2 page To page GO

You may interest

Copyright©2020 药渡经纬信息科技（北京）有限公司电子与信息服务业务经营许可证151001号

京ICP备14047345| 京公安网备11010802017043号 |（京）-经营性-2015-0023（互联网药品信息服务资格证书）

: 药渡APP

: 微信二维码